Kymera Therapeutics, Inc.
KYMR
$24.12
$1.727.68%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -40.11% | 86.92% | 71.38% | 70.16% | 67.84% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -40.11% | 86.92% | 71.38% | 70.16% | 67.84% |
| Cost of Revenue | 27.06% | 23.52% | 19.49% | 14.74% | 15.12% |
| Gross Profit | -74.84% | -1.09% | 2.25% | 6.14% | 5.90% |
| SG&A Expenses | 15.43% | 17.12% | 22.93% | 24.16% | 25.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.44% | 22.07% | 20.24% | 16.74% | 17.32% |
| Operating Income | -55.08% | -5.64% | -4.90% | -2.04% | -2.65% |
| Income Before Tax | -52.32% | -0.01% | -0.16% | 2.80% | 5.07% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -52.32% | -0.01% | -0.16% | 2.80% | 5.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -52.32% | -0.01% | -0.16% | 2.80% | 5.07% |
| EBIT | -55.08% | -5.64% | -4.90% | -2.04% | -2.65% |
| EBITDA | -54.45% | -4.20% | -3.91% | -1.49% | -2.32% |
| EPS Basic | -17.79% | 19.05% | 12.58% | 12.89% | 12.49% |
| Normalized Basic EPS | -15.03% | 21.47% | 15.10% | 15.31% | 12.50% |
| EPS Diluted | -17.79% | 19.05% | 12.58% | 12.89% | 12.49% |
| Normalized Diluted EPS | -15.03% | 21.47% | 15.10% | 15.31% | 12.50% |
| Average Basic Shares Outstanding | 28.48% | 19.61% | 13.91% | 10.64% | 8.16% |
| Average Diluted Shares Outstanding | 28.48% | 19.61% | 13.91% | 10.64% | 8.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
